Elevance Health Stock Analysis – Key Insights Revealed

Large-cap Health Care company Elevance Health has logged a -4.1% change today on a trading volume of 1,533,544. The average volume for the stock is 975,237.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. Based in Indianapolis, United States the company has 104,900 full time employees and a market cap of $121,185,067,008. Elevance Health currently offers its equity investors a dividend that yields 1.1% per year.

The company is now trading -13.88% away from its average analyst target price of $605.45 per share. The 17 analysts following the stock have set target prices ranging from $558.0 to $665.0, and on average give Elevance Health a rating of buy.

Over the last 52 weeks, ELV stock has risen 18.0%, which amounts to a -8.1% difference compared to the S&P 500. The stock's 52 week high is $550.34 whereas its 52 week low is $412.0 per share. With its net margins declining an average -2.2% over the last 6 years, Elevance Health may not have a strong enough profitability trend to support its stock price.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023 171,340,000 5,987,000 3 -25.0
2022 156,595,000 5,894,000 4 0.0
2021 138,639,000 6,158,000 4 0.0
2020 121,867,000 4,572,000 4 -20.0
2019 104,213,000 4,807,000 5 25.0
2018 92,105,000 3,750,000 4
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.